Thus, these findings demonstrate that a new activated pathway, LEF1-miR-HCC1-NFIX, contributes to oncogenic activities in HCC, which could enhance the understanding between miRNAs and HCC development and could have potential value for clinical application in treating HCC. This evidence concerns the gene NFIX and hepatocellular carcinoma.